Every Form 4 that SPRBD (SPRBD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SPRBD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SPRBD filings page.
Spruce Biosciences director Daniel K. Spiegelman received a grant of stock options for 1,700 shares of Common Stock. The options have an exercise price of 52.7000 per share and expire on May 20, 2036. Following this grant, he holds 1,700 derivative securities directly.
The options vest on the first anniversary of the grant date, with full vesting no later than the company’s 2027 annual stockholder meeting, subject to his continuous service under the 2020 Equity Incentive Plan. The award will also vest in full upon a Change in Control as defined in that plan.
Spruce Biosciences director Camilla V. Simpson received a grant of stock options covering 1,700 shares of common stock. The options have an exercise price of $52.70 per share and expire on May 20, 2036. They generally vest on the first anniversary of the grant or by the company’s 2027 annual stockholder meeting, subject to continuous service, with full vesting upon a Change in Control.
SPRUCE BIOSCIENCES, INC. Executive Chairman Michael G. Grey received a grant of stock options covering 1,700 shares of common stock at an exercise price of $52.70 per share. These options vest on the first anniversary of the grant date, will in any case be fully vested by the company’s 2027 annual stockholder meeting, and vest in full upon a Change in Control, all subject to his continuous service under the 2020 Equity Incentive Plan.
Spruce Biosciences director Percival Barretto-Ko received a grant of stock options covering 1,700 shares of Common Stock. The options have an exercise price of $52.70 per share and expire on May 20, 2036.
The grant vests on the first anniversary of the grant date and in any case will be fully vested by the company's 2027 annual stockholder meeting, subject to the director's continuous service under the 2020 Equity Incentive Plan. The options also vest in full upon a Change in Control.
Spruce Biosciences director Keli Walbert received a new stock option grant. The Form 4 shows an award of 1,700 stock options for common stock at an exercise price of $52.70 per share, with 1,700 derivative securities held after the transaction.
The options vest on the first anniversary of the grant date and will in any case be fully vested by the company’s 2027 annual stockholder meeting, subject to continuous service. They also vest in full upon a change in control. This is a compensation-related grant, not an open-market purchase or sale.
Hooks Corwin Dale reported acquisition or exercise transactions in this Form 4 filing.
Spruce Biosciences, Inc. reported that Chief Commercial Officer Corwin Dale Hooks received a grant of 11,000 Restricted Stock Units. Each RSU represents a contingent right to one share of common stock. The units vest in four equal 25% installments each March 15 from 2027 through 2030, conditioned on continued service.
Spruce Biosciences interim Chief Medical Officer Douglas Kirk Ways, who also serves as a director, reported new equity awards and option changes. On December 11, 2025, he was granted 5,000 restricted stock units (RSUs), each representing one share of common stock. According to the vesting terms, 25% (1,250 RSUs) vested on grant and converted into 1,250 shares of common stock at a price of $0, with the remaining RSUs scheduled to vest in three equal 25% installments on December 15, 2026, 2027 and 2028, subject to continuous service.
The filing also details a one-time stock option repricing effective December 11, 2025. Options with exercise prices of $106.09 per share or greater held by eligible employees and directors were amended so their exercise price is $104.13 per share, based on the 30‑day trailing volume‑weighted average price. The options remain fully vested or on their prior vesting schedules, share counts and expiration dates, and if exercised within a one‑year retention period the original higher exercise price must be paid.